


Discovery of Antimycobacterial Spiro-piperidin-4-ones: An Atom Economic, Stereoselective Synthesis and Biological Intervention

Raju Ranjith Kumar,[†] Subbu Perumal,^{*,†} Palaniappan Senthilkumar,[‡] Perumal Yogeeswari,[‡] Dharmarajan Sriram[‡]

[†]Department of Organic Chemistry, School of Chemistry, Madurai Kamaraj University, Madurai 625021, Tamil Nadu, India

[‡]Medicinal Chemistry Research Laboratory, Pharmacy group, Birla Institute of Technology and Science, Pilani 333031, Rajasthan, India

Supplementary Data



Experimental

General

The melting points were measured in open capillary tubes and are uncorrected. The ¹H, ¹³C and the 2D NMR spectra were recorded on a Bruker (Avance) 300 MHz NMR instrument using TMS as internal standard and CDCl₃ as solvent. Standard Bruker software was used throughout. Chemical shifts are given in parts per million (δ -scale) and the coupling constants are given in Hertz. Silica gel-G plates (Merck) were used for TLC analysis with a mixture of petroleum ether (60–80 °C) and ethyl acetate as eluent. Elemental analyses were performed on a Perkin Elmer 2400 Series II Elemental CHNS analyzer.

Synthesis of spiro-[2.3'']-oxindole-spiro[3.3']-1'-methyl-5'-(arylidene)tetrahydro-4'-(1*H*)-pyridinone-4-arylhexahydro-1*H*-pyrrolizine (3).

General procedure. A mixture of **1** (1 mmol), isatin **2** (0.147 g, 1 mmol) and proline (0.115 g, 1 mmol) was dissolved in methanol (10 mL) and warmed on a water bath for 1–2 min. After completion of the reaction as evident from tlc, the mixture was poured into water (50 mL). The precipitated solid was filtered and washed with water to obtain pure **3**.

Spiro[2.3'']oxindole-spiro[3.3']-1'-methyl-5'-(phenylmethyldene)tetrahydro-4'(1*H*)-pyridinone-4-phenylhexahydro-1*H*-pyrrolizine (3a). Obtained as white solid (0.46 g, 95%), m.p. 116–117 °C; [Found: C, 78.57; H, 6.46; N, 8.50. $C_{32}H_{31}N_3O_2$ requires C, 78.50; H, 6.38; N, 8.58%]; δ_H (300 MHz, $CDCl_3$) 8.51 (1 H, s, NH), 6.92 (1 H, s, $C=CH-Ar$), 6.71–7.44 (13 H, m Ar), 4.72 (1 H, ddd, J 11.2, 7.2, 4.2 Hz, 4a-CH), 4.38 (1 H, d, J 11.2 Hz, 4-CH), 3.60 (1 H, dd, J 12.3, 2.1 Hz, 2'- CH_2), 3.41 (1 H, d, J 14.4 Hz, 6'- CH_2), 3.13–3.21 (1 H, m, 7- CH_2), 2.88 (1 H, dd, J 14.4, 2.7 Hz, 6'- CH_2), 2.58–2.65 (1 H, m, 7- CH_2), 2.05 (3 H, s, N- CH_3), 1.89–2.17 (3 H, m, 5- CH_2 and 6- CH_2), 1.78 (1 H, d, J 12.3 Hz, 2'- CH_2), 1.65–1.73 (1 H, m, 5- CH_2); δ_C (75 MHz, $CDCl_3$) 198.2, 179.0, 140.9, 136.6, 135.9, 134.1, 132.9, 128.9, 128.4, 128.0, 127.8, 127.6, 127.3, 127.2, 125.8, 125.3, 120.0, 108.3, 73.3, 70.0, 64.7, 55.7, 55.4, 51.3, 46.9, 43.5, 27.2, 24.5.

Spiro[2.3'']oxindole-spiro[3.3']-1'-methyl-5'-(4-chlorophenylmethyldene)tetrahydro-4'(1*H*)-pyridinone-4-(4-chlorophenyl)hexahydro-1*H*-pyrrolizine (3b). Obtained as white solid (0.52 g, 93%), m.p. 115–117 °C; [Found: C, 68.89; H, 5.31; N, 7.60. $C_{32}H_{29}Cl_2N_3O_2$ requires C, 68.82; H, 5.23; N, 7.52%]; δ_H (300 MHz, $CDCl_3$) 7.90 (1 H, s, NH), 6.65–7.28 (13 H, m Ar), 4.63 (1 H, ddd, J 4.2, 7.2, 11.2 Hz, 4a-CH), 4.32 (1 H, d, J 11.2 Hz, 4-CH), 3.51 (1 H, dd, J 12.3, 2.1 Hz, 2'- CH_2), 3.33 (1 H, d, J 14.4 Hz, 6'- CH_2), 3.14 (1 H, q, J 8.6 Hz, 7- CH_2), 2.87 (1 H, dd, J 14.4, 2.4 Hz, 6'- CH_2), 2.58 (1 H, td, J 8.6, 3.0 Hz, 7- CH_2), 2.09 (3 H, s, N- CH_3), 1.84–2.06 (3 H, m, 5- CH_2 and 6- CH_2), 1.75 (1 H, d, J 12.3 Hz, 2'- CH_2),

1.56–1.64 (1 H, m, 5-CH₂); δ_C (75 MHz, CDCl₃) 198.9, 179.1, 141.7, 136.0, 134.7, 134.1, 133.3, 132.6, 131.0, 130.6, 128.9, 128.5, 128.4, 126.1, 121.0, 109.2, 73.9, 70.6, 65.6, 56.7, 56.4, 51.5, 47.8, 44.6, 27.8, 25.2.

Spiro[2.3"]oxindole-spiro[3.3']-1'-methyl-5'-(4-methylphenylmethyldene)tetrahydro-4'(1*H*)-pyridinone-4-(4-methylphenyl)hexahydro-1*H*-pyrrolizine (3c). Obtained as white solid (0.49 g, 95%), m.p. 114–115 °C; [Found: C, 78.77; H, 6.71; N, 8.19. C₃₄H₃₅N₃O₂ requires C, 78.89; H, 6.81; N, 8.12%]; δ_H (300 MHz, CDCl₃) 8.75 (1 H, s, NH), 6.67–7.27 (13 H, m Ar), 4.68 (1 H, ddd, *J* 3.9, 6.9, 11.1 Hz, 4a-CH), 4.33 (1 H, d, *J* 11.4 Hz, 4-CH), 3.55 (1 H, d, *J* 12.0 Hz, 2'-CH₂), 3.39 (1 H, d, *J* 14.1 Hz, 6'-CH₂), 3.17 (1 H, q, *J* 8.7 Hz, 7-CH₂), 2.88 (1 H, dd, *J* 14.4, 2.4 Hz, 6'-CH₂), 2.57 (1 H, td, *J* 8.7, 2.7 Hz, 7-CH₂), 2.34 (3 H, s, Ar-CH₃), 2.32 (3 H, s, Ar-CH₃), 2.05 (3 H, s, N-CH₃), 1.80–2.11 (3 H, m, 5-CH₂ and 6-CH₂), 1.78 (1 H, d, *J* 12.3 Hz, 2'-CH₂), 1.63–1.70 (1 H, m, 5-CH₂); δ_C (75 MHz, CDCl₃) 199.2, 180.1, 142.0, 138.9, 137.1, 136.3, 134.4, 133.1, 132.3, 130.5, 130.0, 129.2, 128.9, 128.7, 126.3, 120.9, 109.3, 74.4, 70.7, 65.7, 56.8, 56.3, 52.0, 48.0, 44.5, 28.2, 25.3, 21.3, 21.1.

Spiro[2.3"]oxindole-spiro[3.3']-1'-methyl-5'-(4-methoxyphenylmethyldene)tetrahydro-4'(1*H*)-pyridinone-4-(4-chlorophenyl)hexahydro-1*H*-pyrrolizine (3d). Obtained as white solid (0.50 g, 92%), m.p. 105–106 °C; [Found: C, 74.23; H, 6.45; N, 7.68. C₃₄H₃₅N₃O₄ requires C, 74.29; H, 6.42; N, 7.64%]; δ_H (300 MHz, CDCl₃) 9.06 (1 H, s, NH), 6.67–7.29 (13 H, m Ar), 4.63–4.70 (1 H, m, 4a-CH), 4.30 (1 H, d, *J* 11.1 Hz, 4-CH), 3.78 (3 H, s, Ar-OCH₃), 3.77 (3 H, s, Ar-OCH₃), 3.53 (1 H, d, *J* 12.0 Hz, 2'-CH₂), 3.38 (1 H, d, *J* 14.1 Hz, 6'-CH₂), 3.13–3.21 (1 H, m, 7-CH₂), 2.87 (1 H, d, *J* 14.4 Hz, 6'-CH₂), 2.55–2.60 (1 H, m, 7-CH₂), 2.04 (3 H, s, N-CH₃), 1.85–1.97 (3 H, m, 5-CH₂ and 6-CH₂), 1.77 (1 H, d, *J* 12.0 Hz, 2'-CH₂), 1.63–1.69 (1 H, m, 5-CH₂); δ_C (75 MHz, CDCl₃) 199.1, 180.3, 159.9, 158.3, 142.1, 136.9, 131.9, 130.3, 129.5, 128.9, 128.7, 127.7, 126.3, 120.8, 113.7, 113.6, 109.3, 74.5, 70.4, 65.8, 56.9, 56.3, 55.2, 55.1, 51.7, 48.1, 44.6, 28.2, 25.8.

Spiro[2.3"]oxindole-spiro[3.3']-1'-methyl-5'-(4-fluorophenylmethylidene)tetrahydro-4'(1*H*)-pyridinone-4-(4-fluorophenyl)hexahydro-1*H*-pyrrolizine (3e). Obtained as white solid (0.50 g, 96%), m.p. 110–111 °C; [Found: C, 73.25; H, 5.67; N, 8.07. $C_{32}H_{29}F_2N_3O_2$ requires C, 73.13; H, 5.56; N, 7.99%]; δ_H (300 MHz, $CDCl_3$) 8.81 (1 H, s, NH), 6.69–7.33 (13 H, m Ar), 4.59–4.66 (1 H, m, 4a-CH), 4.32 (1 H, d, J 11.4 Hz, 4-CH), 3.52 (1 H, d, J 12.3 Hz, 2'- CH_2), 3.34 (1 H, d, J 14.4 Hz, 6'- CH_2), 3.09–3.17 (1 H, m, 7- CH_2), 2.85 (1 H, dd, J 14.4, 2.4 Hz, 6'- CH_2), 2.54–2.60 (1 H, m, 7- CH_2), 2.05 (3 H, s, N- CH_3), 1.83–1.99 (3 H, m, 5- CH_2 and 6- CH_2), 1.72 (1 H, d, J 12.3 Hz, 2'- CH_2), 1.59–1.70 (1 H, m, 5- CH_2); δ_C (75 MHz, $CDCl_3$) 199.0, 180.0, 142.0, 135.9, 133.5, 133.1, 132.3, 131.7, 131.1, 130.7, 128.9, 126.2, 120.9, 115.7, 115.1, 109.4, 74.2, 70.6, 65.8, 56.6, 56.3, 51.5, 47.9, 44.5, 28.1, 25.3.

Spiro[2.3"]oxindole-spiro[3.3']-1'-methyl-5'-(2-chlorophenylmethylidene)tetrahydro-4'(1*H*)-pyridinone-4-(2-chlorophenyl)hexahydro-1*H*-pyrrolizine (3f). Obtained as white solid (0.53 g, 96%), m.p. 112–114 °C; [Found: C, 68.87; H, 5.10; N, 7.44. $C_{32}H_{29}Cl_2N_3O_2$ requires C, 68.82; H, 5.23; N, 7.52%]; δ_H (300 MHz, $CDCl_3$) 8.66 (1 H, s, NH), 6.70–7.87 (13 H, m Ar), 4.80–4.89 (2 H, m, 4a-CH and 4-CH), 3.50–3.58 (1 H, m, 7- CH_2), 3.29 (1 H, d, J 12.3 Hz, 2'- CH_2), 3.14 (1 H, d, J 14.7 Hz, 6'- CH_2), 2.92 (1 H, dd, J 14.7, 2.4 Hz, 6'- CH_2), 2.56–2.62 (1 H, m, 7- CH_2), 2.04–2.10 (2 H, m, 5- CH_2), 1.94 (3 H, s, N- CH_3), 1.73–1.86 (3 H, m, 2'- CH_2 and 6- CH_2); δ_C (75 MHz, $CDCl_3$) 198.5, 178.5, 142.0, 136.2, 136.1, 135.0, 134.7, 134.2, 134.0, 133.5, 130.7, 129.8, 129.7, 129.5, 129.2, 128.6, 127.8, 126.6, 126.4, 126.2, 121.9, 109.2, 75.6, 67.7, 67.5, 58.0, 57.0, 51.1, 47.9, 45.2, 28.7, 24.9.

Spiro[2.3"]oxindole-spiro[3.3']-1'-methyl-5'-(2-methylphenylmethylidene)tetrahydro-4'(1*H*)-pyridinone-4-(2-methylphenyl)hexahydro-1*H*-pyrrolizine (3g). Obtained as white solid (0.47 g, 92%), m.p. 98–99 °C; [Found: C, 79.02; H, 6.94; N, 8.17. $C_{34}H_{35}N_3O_2$ requires C, 78.89; H, 6.81; N, 8.12%]; δ_H (300 MHz, $CDCl_3$) 8.88 (1 H, s, NH), 6.74–7.71 (13 H, m Ar), 4.77–4.83 (1 H, m, 4a-CH), 4.62 (1 H, d, J 10.5 Hz, 4-CH), 3.62 (1 H, d, J 12.6 Hz, 2'- CH_2), 3.34 (1 H, d, J 14.4 Hz, 6'- CH_2), 3.09–3.17 (1 H, m, 7- CH_2), 2.85 (1 H, dd, J 14.4, 2.4 Hz, 6'- CH_2), 2.54–2.60 (1 H, m, 7- CH_2), 2.05 (3 H, s, N- CH_3), 1.83–1.99 (3 H, m, 5- CH_2 and 6- CH_2), 1.72 (1 H, d, J 12.3 Hz, 2'- CH_2), 1.59–1.70 (1 H, m, 5- CH_2); δ_C (75 MHz, $CDCl_3$) 198.5, 178.5, 142.0, 136.2, 136.1, 135.0, 134.7, 134.2, 134.0, 133.5, 130.7, 129.8, 129.7, 129.5, 129.2, 128.6, 127.8, 126.6, 126.4, 126.2, 121.9, 109.2, 75.6, 67.7, 67.5, 58.0, 57.0, 51.1, 47.9, 45.2, 28.7, 24.9.

CH_2), 3.37–3.45 (1 H, m, 7- CH_2), 3.18 (1 H, d, J 14.7 Hz, 6'- CH_2), 2.87 (1 H, dd, J 14.7, 2.4 Hz, 6'- CH_2), 2.56–2.63 (1 H, m, 7- CH_2), 2.38 (3 H, s, Ar- CH_3), 2.16 (3 H, s, Ar- CH_3), 2.00–2.09 (5 H, s, N- CH_3 , 5- CH_2 and 6- CH_2), 1.80–1.90 (1 H, m, 5- CH_2), 1.74 (1 H, d, J 12.6 Hz, 2'- CH_2), 1.63–1.72 (1 H, m, 5- CH_2); δ_{C} (75 MHz, CDCl_3) 199.4, 179.1, 142.3, 138.3, 137.9, 136.9, 136.8, 134.2, 133.2, 130.4, 130.1, 129.3, 129.0, 128.7, 128.3, 126.6, 125.6, 125.3, 121.3, 109.4, 75.1, 68.6, 68.2, 58.3, 57.1, 49.7, 47.9, 45.0, 28.3, 24.9, 21.1, 20.1.

Spiro[2.3"]oxindole-spiro[3.3']-1'-methyl-5'-(2-methoxyphenylmethylidene)tetrahydro-4'(1H)-pyridinone-4-(2-methoxyphenyl)hexahydro-1H-pyrrolizine (3h). Obtained as white solid (0.52 g, 95%), m.p. 105–107 °C; [Found: C, 74.43; H, 6.56; N, 7.70. $\text{C}_{34}\text{H}_{35}\text{N}_3\text{O}_4$ requires C, 74.29; H, 6.42; N, 7.64%]; δ_{H} (300 MHz, CDCl_3) 8.66 (1 H, s, NH), 7.76 (1 H, s, C=CH), 6.67–7.53 (12 H, m Ar), 4.95–5.02 (1 H, m, 4a-CH), 4.41 (1 H, d, J 11.1 Hz, 4-CH), 3.83 (3 H, s, Ar-OCH₃), 3.71 (3 H, s, Ar-OCH₃), 3.56–3.64 (1 H, m, 7- CH_2), 3.18–3.25 (2 H, m, 2'- CH_2 and 6'- CH_2), 2.91 (1 H, dd, J 15.0, 2.1 Hz, 6'- CH_2), 2.59–2.64 (1 H, m, 7- CH_2), 2.16–2.25 (1 H, m, 5- CH_2), 1.94 (3 H, s, N- CH_3), 1.70–1.88 (4 H, m, 2'- CH_2 , 5- CH_2 and 6- CH_2); δ_{C} (75 MHz, CDCl_3) 198.6, 178.8, 158.4, 158.2, 142.2, 133.0, 132.6, 130.2, 129.8, 129.6, 128.5, 128.2, 127.4, 127.1, 126.7, 124.5, 121.2, 120.4, 119.8, 110.5, 109.7, 109.0, 75.0, 67.5, 64.6, 57.3, 56.6, 55.3, 54.3, 48.4, 47.9, 45.0, 28.2, 24.5.

Spiro[2.3"]oxindole-spiro[3.3']-1'-methyl-5'-(3-fluorophenylmethylidene)tetrahydro-4'(1H)-pyridinone-4-(3-fluorophenyl)hexahydro-1H-pyrrolizine (3i). Obtained as white solid (0.50 g, 96%), m.p. 123–124 °C; [Found: C, 73.06; H, 5.50; N, 8.05. $\text{C}_{32}\text{H}_{29}\text{F}_2\text{N}_3\text{O}_2$ requires C, 73.13; H, 5.56; N, 7.99%]; δ_{H} (300 MHz, CDCl_3) 8.43 (1 H, s, NH), 6.62–7.29 (13 H, m Ar), 4.58–4.66 (1 H, m, 4a-CH), 4.32 (1 H, d, J 11.4 Hz, 4-CH), 3.53 (1 H, dd, J 12.3, 1.8 Hz, 2'- CH_2), 3.35 (1 H, d, J 14.4 Hz, 6'- CH_2), 3.07–3.17 (1 H, m, 7- CH_2), 2.85 (1 H, dd, J 14.4, 2.7 Hz, 6'- CH_2), 2.53–2.60 (1 H, m, 7- CH_2), 2.05 (3 H, s, N- CH_3), 1.83–2.99 (3 H, m, 5- CH_2 and 6- CH_2), 1.72 (1 H, d, J 12.3 Hz, 2'- CH_2), 1.59–1.68 (1 H, m, 5- CH_2); δ_{C} (75

MHz, CDCl₃) 198.8, 179.6, 164.0, 161.1, 141.9, 140.1, 137.0, 135.8, 134.7, 129.8, 129.7, 128.9, 126.1, 125.5, 125.0, 121.1, 116.3, 116.1, 115.6, 113.8, 109.4, 74.0, 70.9, 65.6, 56.5, 56.2, 51.8, 47.8, 44.5, 28.0, 25.3.

Spiro[2.3"]oxindole-spiro[3.3']-1'-methyl-5'-(2,4-dichlorophenylmethyldene)tetrahydro-4'(1H)-pyridinone-4-(2,4-dichlorophenyl)hexahydro-1H-pyrrolizine (3j). Obtained as white solid (0.58 g, 92%), m.p. 112–114 °C; [Found: C, 61.20; H, 4.22; N, 6.77. C₃₂H₂₇Cl₄N₃O₂ requires C, 61.26; H, 4.34; N, 6.70%]; δ_H (300 MHz, CDCl₃) 8.77 (1 H, s, NH), 6.69–7.82 (11 H, m Ar), 4.76 (2 H, s, 4a-CH and 4-CH), 3.46–3.51 (1 H, m, 7-CH₂), 3.23 (1 H, d, *J* 12.3 Hz, 2'-CH₂), 3.09 (1 H, d, *J* 15.0 Hz, 6'-CH₂), 2.91 (1 H, d, *J* 15.0 Hz, 6'-CH₂), 2.56–2.62 (1 H, m, 7-CH₂), 2.07 (2 H, br s, 5-CH₂), 1.96 (3 H, s, N-CH₃), 1.67–1.86 (3 H, m, 2'-CH₂ and 6-CH₂).

Spiro[2.3"]oxindole-spiro[3.3']-1'-methyl-5'-(2-thienylmethyldene)tetrahydro-4'(1H)-pyridinone-4-(2-thienyl)hexahydro-1H-pyrrolizine (3k). Obtained as white solid (0.45 g, 90%), m.p. 106–107 °C; [Found: C, 66.95; H, 5.50; N, 8.32. C₂₈H₂₇N₃O₂S₂ requires C, 67.04; H, 5.42; N, 8.38%]; δ_H (300 MHz, CDCl₃) 8.96 (1 H, s, NH), 6.71–7.46 (11 H, m Ar), 4.60–4.67 (2 H, m, 4a-CH and 4-CH), 3.58 (1 H, d, *J* 12.3 Hz, 2'-CH₂), 3.50 (1 H, d, *J* 15.3 Hz, 6'-CH₂), 3.12–3.20 (1 H, m, 7-CH₂), 2.96 (1 H, dd, *J* 15.3, 2.4 Hz, 6'-CH₂), 2.55–2.62 (1 H, m, 7-CH₂), 1.94 (4 H, s, N-CH₃ and 5-CH₂), 1.96 (1 H, d, *J* 12.3 Hz, 2'-CH₂), 1.84–1.91 (2 H, m, 6-CH₂), 1.69–1.79 (1 H, m, 5-CH₂); δ_C (75 MHz, CDCl₃) 197.5, 180.0, 141.9, 140.4, 138.3, 132.8, 130.5, 129.7, 129.5, 128.9, 127.8, 126.8, 126.0, 125.7, 123.9, 120.9, 109.4, 74.7, 69.8, 67.3, 56.6, 55.2, 48.4, 48.1, 44.6, 28.3, 25.2.

Spiro[2.3"]oxindole-spiro[3.3']-1'-methyl-5'-(1-naphthylmethyldene)tetrahydro-4'(1H)-pyridinone-4-(1-naphthyl)hexahydro-1H-pyrrolizine (3l). Obtained as white solid (0.54 g, 92%), m.p. 109–110 °C; [Found: C, 81.56; H, 6.08; N, 7.21. C₄₀H₃₅N₃O₂ requires C, 81.47; H, 5.98; N, 7.13%]; δ_H (300 MHz, CDCl₃) 8.75 (1 H, s, NH), 6.75–8.57 (19 H, m Ar), 5.27 (1

H, d, *J* 10.5 Hz, 4-CH), 5.00–5.09 (1 H, m, 4a-CH), 3.67 (1 H, d, *J* 12.0 Hz, 2'-CH₂), 3.53–3.61 (1 H, m, 7-CH₂), 3.09 (1 H, d, *J* 14.7 Hz, 6'-CH₂), 2.64–2.74 (2 H, m, 6'-CH₂ and 7-CH₂), 2.03–2.10 (2 H, m, 5-CH₂), 1.91 (4 H, s, N-CH₃ and 6-CH₂), 1.66–1.73 (1 H, m, 6-CH₂), 1.59 (1 H, d, *J* 12.0 Hz, 2'-CH₂); δ_C (75 MHz, CDCl₃) 199.1, 178.9, 142.4, 136.6, 134.8, 134.2, 134.0, 133.7, 133.2, 132.5, 131.2, 129.2, 128.9, 128.7, 128.4, 127.4, 127.0, 126.7, 126.3, 126.1, 125.4, 125.3, 125.1, 124.9, 121.5, 109.6, 77.3, 75.0, 68.9, 68.2, 58.1, 56.8, 48.0, 44.9, 28.1, 24.9.

Spiro[2.3"]oxindole-spiro[3.3']-1'-methyl-5'-(2-furylmethylidene)tetrahydro-4'(1H)-pyridinone-4-(2-furyl)hexahydro-1H-pyrrolizine (3m). Obtained as white solid (0.44 g, 95%), m.p. 146–147 °C; [Found: C, 71.73; H, 5.20; N, 8.84. C₂₈H₂₇N₃O₄ requires C, 71.62; H, 5.08; N, 8.95%]; δ_H (300 MHz, CDCl₃) 9.12 (1 H, s, NH), 6.20–7.44 (11 H, m Ar), 4.55–4.67 (1 H, m, 4a-CH), 4.41 (1 H, d, *J* 10.8 Hz, 4-CH), 3.56–3.60 (2 H, m 2'-CH₂ and 6'-CH₂), 3.12–3.24 (1 H, m, 7-CH₂), 3.02 (1 H, d, *J* 16.2, 6'-CH₂), 2.57–2.64 (1 H, m, 7-CH₂), 2.13 (4 H, s, N-CH₃ and 5-CH₂), 1.65–2.05 (4 H, m, 2'-CH₂, 6-CH₂, and 5-CH₂).

Synthesis of 4-aryl-5-phenylpyrrolo(spiro[2.3"]-oxindole)-spiro[3.3']-1'-methyl-5'-(arylidene)piperidin-4'-ones (4).

General procedure. A mixture of **1** (1 mmol), isatin **2** (0.147 g, 1 mmol) and phenylglycine (0.151 g, 1 mmol) in methanol (10 mL) was refluxed for 1 h. After completion of the reaction as evident from tlc, the mixture was poured into water (50 mL). The precipitated solid was filtered and washed with water to obtain pure **4**. The yield, melting point and NMR spectroscopic data of **4a–f** and **4k–m** agree well with those reported by our group earlier.¹⁷

4-(2-Methylphenyl)-5-phenylpyrrolo(spiro[2.3"]oxindole)spiro[3.3']-1'-methyl-5'-(2-methylphenylmethylidene)piperidin-4'-one (4g). Obtained as white solid (0.53 g, 95%), m.p. 166–167 °C; [Found: C, 80.36; H, 6.30; N, 7.70. C₃₇H₃₅N₃O₂ requires C, 80.26; H, 6.37; N, 7.59%]; δ_H (300 MHz, CDCl₃) 7.94 (1 H, br s, 1"-NH), 6.69–7.56 (18 H, m, Ar-H), 5.51 (1

H, d, *J* 9.9 Hz, 5-CH), 4.91 (1 H, d, *J* 9.9 Hz, 4-CH), 3.37 (1 H, d, *J* 12.9 Hz, 2'-CH₂), 3.21 (1 H, d, *J* 15.0 Hz, 6'-CH₂), 2.94 (1 H, dd, *J* 15.0, 2.7 Hz, 6'-CH₂), 2.18 (3 H, s, Ar-CH₃), 2.14 (3 H, s, Ar-CH₃), 2.01 (3 H, s, N-CH₃), 1.82 (1 H, d, *J* 12.9 Hz, 2'-CH₂); δ_C (75 MHz, CDCl₃) 199.3, 180.0, 141.5, 141.3, 138.0, 136.9, 136.2, 134.2, 132.9, 130.1, 129.3, 128.7, 128.4, 128.3, 127.4, 126.8, 126.4, 125.7, 125.4, 122.3, 109.1, 73.3, 65.9, 65.0, 58.4, 57.2, 53.1, 45.4, 21.0, 20.1.

4-(2-Methoxyphenyl)-5-phenylpyrrolo(spiro[2.3"]oxindole)spiro[3.3']-1'-methyl-5'-(2-methoxyphenylmethylidene)piperidin-4'-one (4h). Obtained as white solid (0.55 g, 94%), m.p. 190–191 °C; [Found: C, 75.80; H, 6.14; N, 7.11. C₃₇H₃₅N₃O₄ requires C, 75.88; H, 6.02; N, 7.17%]; δ_H (300 MHz, CDCl₃) 7.78 (1 H, br s, 1"-NH), 6.67–7.68 (18 H, m, Ar-H), 5.51 (1 H, d, *J* 9.9 Hz, 5-CH), 4.92 (1 H, d, *J* 9.9 Hz, 4-CH), 3.85 (3 H, s, Ar-OCH₃), 3.68 (3 H, s, Ar-OCH₃), 3.26 (1 H, d, *J* 15.0 Hz, 6'-CH₂), 2.97 (1 H, d, *J* 15.0 Hz, 6'-CH₂), 1.98 (3 H, s, N-CH₃), 1.96 (1 H, d, *J* 12.3 Hz, 2'-CH₂).

4-(3-Fluorophenyl)-5-phenylpyrrolo(spiro[2.3"]oxindole)spiro[3.3']-1'-methyl-5'-(3-fluorophenylmethylidene)piperidin-4'-one (4i). Obtained as white solid (0.54 g, 96%), m.p. 159–161 °C; [Found: C, 74.76; H, 5.29; N, 7.40. C₃₅H₂₉F₂N₃O₂ requires C, 74.85; H, 5.20; N, 7.48%]; δ_H (300 MHz, CDCl₃) 8.02 (1 H, br s, 1"-NH), 6.78–7.67 (18 H, m, Ar-H), 5.53 (1 H, d, *J* 9.9 Hz, 5-CH), 4.95 (1 H, d, *J* 9.9 Hz, 4-CH), 3.30 (1 H, d, *J* 12.9 Hz, 2'-CH₂), 3.20 (1 H, d, *J* 15.0 Hz, 6'-CH₂), 2.93 (1 H, d, *J* 15.0 Hz, 6'-CH₂), 2.00 (3 H, s, N-CH₃), 1.80 (1 H, d, *J* 12.9 Hz, 2'-CH₂).

4-(2,4-Dichlorophenyl)-5-phenylpyrrolo(spiro[2.3"]oxindole)spiro[3.3']-1'-methyl-5'-(2,4-dichlorophenylmethylidene)piperidin-4'-one (4j). Obtained as white solid (0.63 g, 95%), m.p. 189–190 °C; [Found: C, 63.27; H, 4.00; N, 6.40. C₃₅H₂₇Cl₄N₃O₂ requires C, 63.36; H, 4.10; N, 6.33%]; δ_H (300 MHz, CDCl₃) 8.01 (1 H, br s, 1"-NH), 6.93–7.71 (18 H, m, Ar-H), 5.55 (1 H, d, *J* 9.3 Hz, 5-CH), 5.07 (1 H, d, *J* 9.3 Hz, 4-CH), 3.16 (1 H, d, *J* 15.0 Hz, 6'-CH₂),

2.96–3.01 (2 H, m, 2'-CH₂ and 6'-CH₂), 1.97 (3 H, s, N-CH₃), 1.93 (1 H, d, *J* 12.6 Hz, 2'-CH₂); δ_C (75 MHz, CDCl₃) 198.4, 178.6, 141.4, 140.5, 136.7, 135.9, 135.1, 134.8, 134.1, 133.5, 133.0, 131.8, 131.4, 130.5, 129.7, 129.0, 128.8, 128.6, 127.9, 127.6, 127.5, 127.1, 126.7, 126.5, 122.7, 109.1, 74.3, 65.3, 64.0, 57.8, 57.1, 53.3, 45.6.

Synthesis of 1-methyl-4-arylpyrrolo-(spiro[2.3"]oxindole)-spiro[3.3']-1'-methyl-5'-(arylidene)piperidin-4'-ones (5).

General procedure. A mixture of **1** (1 mmol), isatin **2** (0.147 g, 1 mmol) and sarcosine (0.089 g, 1 mmol) were dissolved in methanol (10 mL) and refluxed for 30 min. After completion of the reaction as evident from tlc, the mixture was poured into water (50 mL). The precipitated solid was filtered and washed with water to obtain pure **5**. The physical and spectroscopic data of **5a–d** agree well with those reported in the literature.²⁰

1-Methyl-4-(4-fluorophenyl)pyrrolo-(spiro[2.3"]oxindole)-spiro[3.3']-1'-methyl-5'-(4-fluorophenylmethylidene)piperidin-4'-one (5e). Obtained as white solid (0.45 g, 91%), m.p. 178–179 °C; [Found: C, 72.19; H, 5.39; N, 8.47. C₃₀H₂₇F₂N₃O₂ requires C, 72.13; H, 5.45; N, 8.41%]; δ_H (300 MHz, CDCl₃) 8.56 (1 H, s, NH), 6.67–7.39 (13 H, m, Ar), 4.80 (1 H, dd, *J* 10.8, 10.8 Hz, 4-CH), 3.89 (1 H, t, *J* 10.8 Hz, 5-CH₂), 3.25–3.35 (3 H, m, 5-CH₂, 2'-CH₂ and 6'-CH₂), 2.91 (1 H, dd, *J* 14.1, 2.1 Hz, 6'-CH₂), 2.15 (3 H, s, 1-N-CH₃), 2.05 (3 H, s, 1'-N-CH₃), 1.67 (1 H, d, *J* 12.6 Hz, 2'-CH₂); δ_C (75 MHz, CDCl₃) 198.4, 177.9, 142.0, 136.4, 133.9, 133.1, 131.8, 131.2, 130.7, 128.7, 127.6, 127.5, 121.8, 115.3, 114.9, 108.9, 75.6, 66.0, 57.0, 56.8, 56.6, 44.7, 44.6, 34.6.

1-Methyl-4-(2-chlorophenyl)pyrrolo-(spiro[2.3"]oxindole)-spiro[3.3']-1'-methyl-5'-(2-chlorophenylmethylidene)piperidin-4'-one (5f). Obtained as white solid (0.48 g, 90%), m.p. 200–202 °C; [Found: C, 67.75; H, 5.09; N, 7.81. C₃₀H₂₇Cl₂N₃O₂ requires C, 67.67; H, 5.11; N, 7.89%]; δ_H (300 MHz, CDCl₃) 8.53 (1 H, s, NH), 7.61 (1 H, s, C=CH), 6.71–8.00 (12 H, m, Ar), 5.12 (1 H, t, *J* 8.7 Hz, 4-CH), 3.96 (1 H, t, *J* 9.0 Hz, 5-CH₂), 3.48 (1 H, t, *J* 9.0

Hz, 5-CH₂), 3.14 (1 H, d, *J* 14.7 Hz, 6'-CH₂), 2.90–3.01 (2 H, m, 2'-CH₂ and 6'-CH₂), 2.12 (3 H, s, 1-N-CH₃), 1.92 (3 H, s, 1'-N-CH₃), 1.82 (1 H, d, *J* 12.6 Hz, 2'-CH₂); δ_C (75 MHz, CDCl₃) 197.3, 177.8, 142.0, 136.9, 135.8, 134.9, 134.6, 134.0, 133.6, 130.7, 129.9, 129.7, 129.2, 128.5, 127.9, 127.8, 126.6, 126.5, 126.1, 122.7, 108.9, 77.2, 63.6, 57.8, 57.7, 57.0, 45.4, 42.1, 34.7.

1-Methyl-4-(2-methylphenyl)pyrrolo-(spiro[2.3"]oxindole)-spiro[3.3']-1'-methyl-5'-(2-methylphenylmethylidene)piperidin-4'-one (5g). Obtained as white solid (0.45 g, 91%), m.p. 180–181 °C; [Found: C, 78.10; H, 6.84; N, 8.64. C₃₂H₃₃N₃O₂ requires C, 78.18; H, 6.77; N, 8.55%]; δ_H (300 MHz, CDCl₃) 8.85 (1 H, s, NH), 7.51 (1 H, s, C=CH), 6.76–7.85 (12 H, m, Ar), 4.99 (1 H, t, *J* 9.6 Hz, 4-CH), 4.02 (1 H, t, *J* 9.6 Hz, 5-CH₂), 3.42 (1 H, t, *J* 8.4 Hz, 5-CH₂), 3.28 (1 H, d, *J* 12.9 Hz, 2'-CH₂), 3.18 (1 H, d, *J* 14.7 Hz, 6'-CH₂), 2.89 (1 H, dd, *J* 14.7, 2.4 Hz, 6'-CH₂), 2.31 (3 H, s, Ar-CH₃), 2.15 (3 H, s, Ar-CH₃), 2.14 (3 H, s, 1-N-CH₃), 1.96 (3 H, s, 1'-N-CH₃), 1.68 (1 H, d, *J* 12.9 Hz, 2'-CH₂); δ_C (75 MHz, CDCl₃) 198.5, 178.0, 142.3, 138.0, 137.8, 137.1, 137.0, 134.3, 133.0, 130.2, 130.1, 129.3, 128.6, 128.3, 127.8, 127.3, 126.5, 125.7, 125.3, 122.3, 109.1, 76.9, 64.2, 58.4, 57.2, 45.3, 41.6, 34.7, 21.2, 20.1.

1-Methyl-4-(2-methoxyphenyl)pyrrolo-(spiro[2.3"]oxindole)-spiro[3.3']-1'-methyl-5'-(2-methoxyphenylmethylidene)piperidin-4'-one (5h). Obtained as white solid (0.50 g, 96%), m.p. 197–199 °C; [Found: C, 73.47; H, 6.30; N, 8.09. C₃₂H₃₃N₃O₄ requires C, 73.40; H, 6.35; N, 8.02%]; δ_H (300 MHz, CDCl₃) 8.79 (1 H, s, NH), 7.69 (1 H, s, C=CH), 6.69–7.62 (12 H, m, Ar), 4.90 (1 H, dd, *J* 10.8, 10.5 Hz, 4-CH), 4.11 (1 H, t, *J* 9.9 Hz, 5-CH₂), 3.82 (3 H, s, Ar-OCH₃), 3.72 (3 H, s, Ar-OCH₃), 3.34 (1 H, t, *J* 8.1 Hz, 5-CH₂), 3.22 (1 H, d, *J* 14.4 Hz, 6'-CH₂), 3.02 (1 H, d, *J* 12.3 Hz, 2'-CH₂), 2.90 (1 H, d, *J* 14.7 Hz, 6'-CH₂), 2.14 (3 H, s, 1-N-CH₃), 1.93 (3 H, s, 1'-N-CH₃), 1.82 (1 H, d, *J* 12.3 Hz, 2'-CH₂); δ_C (75 MHz, CDCl₃) 197.3, 178.0, 158.1, 158.0, 142.3, 133.1, 132.6, 130.1, 129.8, 128.5, 128.1, 127.6, 127.4, 127.3,

124.5, 122.0, 120.3, 119.7, 110.5, 109.8, 108, 7, 77.0, 63.8, 57.0, 56.7, 55.8, 55.3, 54.8, 45.3, 39.3, 34.8.

1-Methyl-4-(3-fluorophenyl)pyrrolo-(spiro[2.3"]oxindole)-spiro[3.3']-1'-methyl-5'-(3-fluorophenylmethylidene)piperidin-4'-one (5i). Obtained as white solid (0.47 g, 94%), m.p. 175–177 °C; [Found: C, 72.07; H, 5.37; N, 8.49. $C_{30}H_{27}F_2N_3O_2$ requires C, 72.13; H, 5.45; N, 8.41%]; δ_H (300 MHz, $CDCl_3$) 8.77 (1 H, s, NH), 6.65–7.29 (13 H, m, Ar), 4.81 (1 H, dd, *J* 11.1, 10.8 Hz, 4-CH), 3.90 (1 H, dd, *J* 11.1, 11.1 Hz, 5- CH_2), 3.29–3.37 (3 H, m, 5- CH_2 , 2'- CH_2 and 6'- CH_2), 2.92 (1 H, dd, *J* 15.0, 2.7 Hz, 6'- CH_2), 2.16 (3 H, s, 1-N-CH₃), 2.05 (3 H, s, 1'-N-CH₃), 1.71 (1 H, d, *J* 12.6 Hz, 2'- CH_2); δ_C (75 MHz, $CDCl_3$) 198.2, 177.9, 164.1, 160.9, 142.1, 140.9, 137.1, 136.1, 134.3, 129.8, 129.6, 129.5, 128.9, 127.6, 127.4, 125.5, 125.0, 121.9, 116.3, 116.0, 115.5, 113.7, 109.0, 75.5, 66.3, 56.8, 56.7, 56.2, 45.0, 44.7, 34.5.

1-Methyl-4-(2,4-dichlorophenyl)pyrrolo-(spiro[2.3"]oxindole)-spiro[3.3']-1'-methyl-5'-(2,4-dichlorophenylmethylidene)piperidin-4'-one (5j). Obtained as white solid (0.58 g, 96%), m.p. 215–217 °C; [Found: C, 59.82; H, 4.29; N, 6.91. $C_{30}H_{25}Cl_4N_3O_2$ requires C, 59.92; H, 4.19; N, 6.99%]; δ_H (300 MHz, $CDCl_3$) 8.63 (1 H, s, NH), 7.50 (1 H, s, C=CH), 6.71–8.00 (10 H, m, Ar), 5.05 (1 H, t, *J* 8.4 Hz, 4-CH), 3.86 (1 H, t, *J* 9.0 Hz, 5- CH_2), 3.47 (1 H, t, *J* 8.4 Hz, 5- CH_2), 3.10 (1 H, d, *J* 14.7 Hz, 6'- CH_2), 2.89–2.96 (2 H, m, 2'- CH_2 and 6'- CH_2), 2.10 (3 H, s, 1-N-CH₃), 1.94 (3 H, s, 1'-N-CH₃), 1.80 (1 H, d, *J* 12.6 Hz, 2'- CH_2); δ_C (75 MHz, $CDCl_3$) 197.0, 177.8, 142.0, 136.3, 135.6, 135.5, 134.9, 134.4, 133.5, 132.9, 132.0, 131.7, 130.5, 129.6, 128.9, 128.7, 127.8, 127.0, 126.6, 126.3, 122.6, 109.0, 77.0, 63.5, 57.8, 57.7, 56.9, 45.4, 41.7, 34.7.

1-Methyl-4-(2-thienyl)pyrrolo-(spiro[2.3"]oxindole)-spiro[3.3']-1'-methyl-5'-(2-thienylmethylidene)piperidin-4'-one (5k). Obtained as white solid (0.46 g, 96%), m.p. 196–198 °C; [Found: C, 65.61; H, 5.37; N, 8.87. $C_{26}H_{25}N_3O_2S_2$ requires C, 65.66; H, 5.30; N, 8.83%]; δ_H (300 MHz, $CDCl_3$) 7.94 (1 H, s, NH), 6.82–7.61 (11 H, m, Ar), 5.05 (1 H, dd, *J* 11.1, 10.8

Hz, 4-CH), 3.89 (1 H, dd, *J* 10.8, 10.8 Hz, 5-CH₂), 3.48 (1 H, d, *J* 12.6 Hz, 2'-CH₂), 3.32–3.43 (2 H, m, 5-CH₂ and 6'-CH₂), 3.01 (1 H, d, *J* 15.6 Hz, 6'-CH₂), 2.17 (3 H, s, 1-N-CH₃), 2.15 (3 H, s, 1'-N-CH₃), 1.95 (1 H, d, *J* 12.6 Hz, 2'-CH₂).

1-Methyl-4-(1-naphthyl)pyrrolo-(spiro[2.3"]oxindole)-spiro[3.3']-1'-methyl-5'-(1-naphthylmethylidene)piperidin-4'-one (5l). Obtained as white solid (0.46 g, 92%), m.p. 224–225 °C; [Found: C, 80.89; H, 5.97; N, 7.49. C₃₈H₃₃N₃O₂ requires C, 80.97; H, 5.90; N, 7.45%]; δ_H (300 MHz, CDCl₃) 8.82 (1 H, s, NH), 7.97 (1 H, s, C=CH), 6.77–8.35 (18 H, m, Ar), 5.70 (1 H, t, *J* 9.6 Hz, 4-CH), 4.22 (1 H, t, *J* 9.6 Hz, 5-CH₂), 3.53 (1 H, t, *J* 8.1 Hz, 5-CH₂), 3.39 (1 H, d, *J* 12.6 Hz, 2'-CH₂), 3.05 (1 H, d, *J* 14.7 Hz, 6'-CH₂), 2.68 (1 H, dd, *J* 14.7, 2.4 Hz, 6'-CH₂), 2.22 (3 H, s, 1-N-CH₃), 1.85 (3 H, s, 1'-N-CH₃), 1.56 (1 H, d, *J* 12.6 Hz, 2'-CH₂); δ_C (75 MHz, CDCl₃) 198.2, 177.9, 142.5, 136.6, 134.8, 134.7, 133.8, 133.2, 132.5, 131.2, 128.9, 128.8, 128.7, 128.4, 128.0, 127.4, 127.3, 127.0, 126.5, 126.2, 126.1, 125.4, 125.3, 125.1, 124.9, 124.8, 124.5, 122.4, 109.3, 76.9, 64.9, 58.7, 57.9, 56.9, 45.0, 40.1, 34.8.

MIC determination

All compounds were screened for their *in vitro* antimycobacterial activity against MTB, MDR-TB and MC² in Middlebrook 7H11agar medium supplemented with OADC by agar dilution method similar to that recommended by the National Committee for Clinical Laboratory Standards for the determination of MIC in duplicate.¹⁹ The MDR-TB clinical isolate was obtained from Tuberculosis Research Center, Chennai, India, and was resistant to isoniazid, rifampicin, ethambutol and ofloxacin. The minimum inhibitory concentration (MIC) is defined as the minimum concentration of compound required to give complete inhibition of bacterial growth.

Cytotoxicity

All the compounds were further examined for toxicity (IC_{50}) in a mammalian Vero cell line upto concentration of $62.5 \mu\text{g/mL}^{21}$ by serial dilution method. After 72 h of exposure, viability was assessed on the basis of cellular conversion of MTT into a formazan product using the Promega Cell Titer 96 non-radioactive cell proliferation assay.

***In vivo* studies**

One compound was tested for efficacy against MTB at a dose of 25 mg/kg in six-week-old female CD-1 mice six per group. In this model, the mice were infected intravenously through caudal vein approximately 10^7 viable *Mycobacterium tuberculosis* ATCC 35801. Drug treatment by intra peritoneal route began after 10 days of inoculation of the animal with microorganism and continued for 10 days. After 35 days post infection the spleens and right lungs were aseptically removed and ground in a tissue homogenizer, the number of viable organisms was determined by serial 10-fold dilutions and subsequent inoculation onto 7H10 agar plates. Cultures were incubated at 37°C in ambient air for 4 weeks prior to counting. Bacterial counts were measured, and compared with the counts from negative controls (vehicle treated) in lung and in spleen (Table 2).